110873 ⎘
ssRNA viruses negative-sense; Details; Paramyxoviridae New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
LIPID PARTICLES COMPRISING VARIANT PARAMYXOVIRUS ATTACHMENT GLYCOPROTEINS AND USES THEREOF
#2FUSOSOME COMPOSITIONS AND USES THEREOF
#3Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus F proteins and their use
#4PARAMYXOVIRUS VIRUS-LIKE PARTICLES AS PROTEIN DELIVERY VEHICLES
#5METHODS OF REPEAT DOSING AND ADMINISTRATION OF LIPID PARTICLES OR VIRAL VECTORS AND RELATED SYSTEMS AND USES
#6Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus F proteins and their use
#7Self-Assembling Protein Nanostructures Displaying Paramyxovirus and/or Pneumovirus F Proteins and Their Use
#8Paramyxovirus virus-like particles as protein delivery vehicles
#9RNA CONSTRUCT
#10Self-assembled protein nanoparticle and its applications thereof
#11Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus F proteins and their use
#12PARAMYXOVIRUS VIRUS-LIKE PARTICLES AS PROTEIN DELIVERY VEHICLES
#13Chimeric molecules and uses thereof
#14FUSOSOME COMPOSITIONS AND USES THEREOF
#15Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus F proteins and their use
#16Chimeric molecules and uses thereof
#17Paramyxovirus virus-like particles as protein delivery vehicles
#18Paramyxovirus virus-like particles as protein delivery vehicles
#19ATTENUATED NEGATIVE STRAND VIRUSES WITH ALTERED INTERFERON ANTAGONIST ACTIVITY FOR USE AS VACCINES AND PHARMACEUTICALS
#20Compositions and methods comprising hydrocarbon-stapled polypeptides
#21COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
#22POLYPEPTIDES AND THEIR USE IN TREATING METAPNEUMOVIRUS (MPV) INFECTION
#23Cells and methodology to generate non-segmented negative-strand RNA viruses
#24Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
#25Mutant proteins of the F protein of PIV-5 and PIV-2
#26Compositions and methods for the treatment of viral infections
#27Mutant proteins of the F protein of PIV-5 and PIV-2
#28FUSION PROTEINS COMPRISING DP-178 AND OTHER VIRAL FUSION INHIBITOR PEPTIDES USEFUL FOR TREATING AIDS
#29VECTORS WITH MODIFIED PROTEASE-DEPENDENT TROPISM
#30METHODS AND COMPOSITIONS FOR INHIBITION OF MEMBRANE FUSION-ASSOCIATED EVENTS, INCLUDING HIV TRANSMISSION
#31NOVEL METHODS AND INTERFERON DEFICIENT SUBSTRATES FOR THE PROPAGATION OF VIRUSES
#32Recombinant viruses comprising the membrane-proximal domain of VSV G protein
#33ATTENUATED NEGATIVE STRAND VIRUSES WITH ALTERED INTERFERON ANTAGONIST ACTIVITY FOR USE AS VACCINES AND PHARMACEUTICALS
#34Cells and methodology to generate non-segmented negative-strand RNA viruses
#35RECOMBINANT PROTEINS AND VIRUS LIKE PARTICLES COMPRISING L AND S POLYPEPTIDES OF AVIAN HEPADNAVIRIDAE AND METHODS, NUCLEIC ACID CONSTRUCTS, VECTORS AND HOST CELLS FOR PRODUCING SAME
#36Methods for the propagation of modified influenza viruses in embryonated eggs
#37N protein of a virus of the paramyxoviridae family-protein of interest fusion proteins
#38COMBINATION VACCINE COMPRISING AN ATTENUATED BOVINE VIRAL DIARRHEA VIRUS
#39Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
#40Vectors with modified protease-dependent tropism
#41Antifusogenic proteins comprising human immunodeficiency virus type 1 (HIV-1) gp41 DP-178 polypeptide variants and a macromolecular carrier
#42Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
#43Flexible vaccine assembly and vaccine delivery platform
#44Method for the recovery of non-segmented, nagative-stranded RNA viruses from cDNA
#45Chris-like virus, compositions, vaccines and uses thereof
#46Vectors with modified protease-dependent tropism
#47Methods and interferon deficient substrates for the propagation of viruses